Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00213876
First received: September 13, 2005
Last updated: August 29, 2011
Last verified: August 2011

September 13, 2005
August 29, 2011
February 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00213876 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours
Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.

At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patient with oligodendroglioma or medulloblastoma or glioma

Oligodendrogliomas
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
189
August 2011
Not Provided

Inclusion Criteria:

  • Paediatric and adult patients (> 1 year of age)
  • Patient with oligodendroglioma or medulloblastoma or glioma
  • Possibility of 3 year follow-up
  • Patient consent obtained

Exclusion Criteria:

-

Both
1 Year and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00213876
3154
Not Provided
Not Provided
University Hospital, Strasbourg, France
Not Provided
Principal Investigator: Natacha Entz-Werle, MD Hopitaux Universitaires de Strasbourg
University Hospital, Strasbourg, France
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP